Redefining Early Oncology R&D: What ASCO 2026 Reveals About the Future of Precision-Driven Development

At the American Society of Clinical Oncology (ASCO) 2026 annual meeting, a clear takeaway emerged: Oncology innovation has entered a new era, one no longer defined solely by new drugs, but by how deeply biology, diagnostics, and research and development strategy are integrated from the very beginning of therapy development.

Multiple plenary sessions and scientific presentations demonstrated that precision oncology is becoming fully integrated into clinical research and care. Biomarkers are no longer simply used to stratify patients. They are actively guiding treatment decisions, informing trial design approaches, and shaping how therapies are developed and provided to patients.

This allows early-phase oncology studies to generate deeper biological insights. Phase 1 and 2 development is increasingly strategic, biomarker-driven, and decisive for downstream success.

For the emerging biopharma companies (EBPs) propelling much of the early-stage innovation in oncology drug discovery and development, this shift underscores the growing importance of adapting clinical strategies accordingly. 

Biomarkers: From stratification to decision-making

Perhaps the most visible signal of this transformation at ASCO 2026 was the evolving role of biomarkers.

The OPTIMA Phase 3 trial demonstrated that genomic testing can direct adjuvant therapy, safely sparing approximately two-thirds of patients with high clinical risk ER-positive HER2-negative early breast cancer from chemotherapy while achieving comparable outcomes. This reflects a change in perspective on the design of treatment regimens in oncology.

Beyond improving efficacy, precision medicine is increasingly enabling more selective use of treatment and helping to identify patients who can avoid the physical and long-term toxicities of chemotherapy without compromising outcomes.

It also reflects a broader move toward more personalized, risk-adapted care, where treatment decisions balance clinical benefit with quality of life and the avoidance of unnecessary intervention.

This approach aligns with broader shifts in regulatory thinking, such as the US Food and Drug Administration’s Project Optimus initiative, which emphasizes identifying optimal treatment regimens and minimizing toxicity rather than defaulting to the highest tolerable dose.

At the same time, technologies such as circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing promote a dynamic and continuous understanding of disease. Instead of relying entirely on imaging or biopsies, clinicians can also monitor cancer progression or remission through blood-based assays.

Several ASCO 2026 presentations illustrated this trend. For example, the PREDICT-RD Phase 2 study of early triple-negative breast cancer demonstrated how ctDNA-based surveillance can detect molecular residual disease before clinical or radiographic evidence of relapse, enabling earlier, biomarker-informed treatment decisions.

Further reinforcing ctDNA’s role as a longitudinal biomarker, a sub-study of the Phase 2/3 PARTNER study in neoadjuvant therapy of triple-negative breast cancer found that post-treatment ctDNA positivity is highly prognostic for distant recurrence and outperforms pathologic complete response for risk stratification.

Pan-cancer evidence further supports these findings. MONSTAR‑SCREEN‑3 prospective analyses showed that ctDNA positivity after curative-intent treatment was associated with significantly worse disease-free survival, demonstrating both the prognostic value of post-treatment ctDNA and the ability of ultra-sensitive assays to detect residual disease at very low levels.

Together, these data underscore how persistent or newly detectable ctDNA is strongly associated with recurrence risk.

At the same time, ctDNA is enabling real-time monitoring of disease progression across multiple biological samples, including blood, urine, and cerebrospinal fluid, depending on the tumor type. This supports more continuous, less invasive assessments of patient response and reduces reliance on tissue biopsies. 

Early-phase: From exploratory to strategic

From molecular diagnosis to therapy selection and longitudinal observation, these capabilities are increasingly being integrated into a continuous loop to enable a more adaptive and responsive approach to cancer treatment. This has critical implications for EBPs.

Drug development can no longer proceed independently of biomarker strategy. Success increasingly depends on the ability to simultaneously develop therapeutics, diagnostics, and patient selection approaches at the earliest stages of development.

Circulating Immune Proteins in Liver Cancer Research

This webinar explores how circulating immune-related proteins can improve our understanding of hepatocellular and gallbladder cancer risk across diverse populations with viral hepatitis.
View Webinar

Advertisement

This integration of biology and diagnostics is transforming the nature of early-phase oncology. Historically, Phase 1 trials focused primarily on safety and dose-finding.

Today, initial phases are increasingly designed with clear efficacy and monitoring strategies to enable early biological and clinical insights that inform critical development decisions and support more efficient downstream progression in a highly competitive oncology R&D landscape.

Late-stage results presented at ASCO 2026 reflect the impact of increasingly strategic early-phase development. Most notable was the RASolute 302 Phase 3I study of daraxonrasib, a RAS(ON) multi-selective inhibitor, for previously-treated metastatic pancreatic cancer, which showed a 60% reduction in risk of death compared to chemotherapy. Activity was observed across both KRAS-mutant and non-mutant populations.

This emphasizes an important nuance in precision oncology: While some approaches target narrowly defined biomarker populations, others may deliver broader benefit depending on the underlying mechanism of action.

This breakthrough is significant not only for its clinical impact but also for what it represents scientifically. KRAS was long considered “undruggable,” yet advances in molecular design are creating opportunities to attenuate targets and pathways previously considered inaccessible.

These innovations extend beyond a single disease, pointing to more modular, platform-based strategies that could reshape how therapies are developed across oncology.

At the same time, precision approaches are becoming increasingly granular. Biomarker-defined subpopulations based on genomic, transcriptomic, or immune signatures are enabling more targeted interventions. This introduces new layers of complexity in patient identification and trial design.

Liquid Biopsies in Cancer: Technologies, Applications, and Emerging Advances

This infographic provides an overview of liquid biopsy workflows, applications, and innovations addressing current limitations.

View Infographic

Advertisement

As treatments become more focused, patient populations required for clinical trials will become smaller and more restrictive. Trial sponsors will need to adapt operationally to support these deeper scientific insights, including: 

• More complex recruitment strategies.
• Greater reliance on biomarker testing infrastructure.
• Increased need for adaptive, flexible trial designs.
   

These pressures underscore the reality that early-phase oncology is no longer just an initial step in development. It can be when differentiation, positioning in the therapeutic space, and probability of success are established. 

Next-generation modalities and combination approaches: From innovation to elevated standards

ASCO 2026 also highlighted the rapid rise of next-generation therapeutic modalities, including bispecific antibodies, antibody-drug conjugates, and engineered cell therapies.

Late-stage results, such as those for ivonescimab, illustrate how multi-modal strategies—often shaped during earlier phases of development—are translating into improved clinical outcomes.

In the HARMONi‑6 Phase 3 study, the PD‑1 × VEGF bispecific antibody combined with chemotherapy demonstrated a significant improvement in overall survival compared with standard immunotherapy plus chemotherapy in advanced squamous non-small cell lung cancer.

The treatment reduced the risk of death by approximately 34% and extended median survival to nearly 28 months. Notably, the benefit was observed regardless of PD‑L1 expression, indicating potential to broaden the impact of immunotherapy beyond biomarker-selected populations.

This reflects a growing trend in oncology innovation. Rather than relying on single mechanisms of action, therapies are increasingly designed to target multiple pathways simultaneously, integrating immune activation, tumor microenvironment modulation, and direct cytotoxic effects.

This evolution reflects a convergence in scientific approaches, in which modalities such as personalized mRNA vaccines and in vivo cell therapies draw on shared, programmable technologies, particularly mRNA and lipid nanoparticle delivery platforms, to enable diverse applications from a common foundation.

At ASCO 2026, this was exemplified by results from the KEYNOTE 942 Phase 2b study, in which an individualized neoantigen mRNA vaccine combined with PD-1 checkpoint inhibitor pembrolizumab reduced recurrence risk by 49% and distant metastasis by 59% in individuals with high-risk resected melanoma.

Diving Into Multiomics: From Data to Discovery

This infographic explores the key multiomics fields, their integration across research applications, and real-world case studies spanning cancer, diabetes, agriculture, and environmental science.
View Infographic

Advertisement

Further, early-stage data from in vivo cell therapy approaches, such as the first-in-human study of GT801 in patients with B-cell hematologic malignancies, demonstrate emerging strategies to generate therapeutic activity directly within patients using similar RNA-based delivery principles.

This convergence is reshaping how therapies are conceptualized and developed. The focus is moving from discovering individual drugs to engineering integrated treatment strategies. As such, trial sponsors need to keep in mind that therapies designed to work through multiple mechanisms simultaneously will require: 

• Sophisticated translational models to understand interactions.
• Meticulous safety assessment for overlapping toxicities.
• Integration and optimal sequencing with existing therapies.
• Biomarker strategies to identify potentially responsive patients.

These challenges should be addressed up front. In particular, delaying alignment of biomarker and companion diagnostic strategies until later trial phases may introduce downstream complexity detrimental to timelines, costs, and overall efficiency. For EBPs, as investors place increasing emphasis on strategic clarity and disciplined execution, early integration of these elements is becoming an important component of how programs are de-risked and differentiated. 

Redefining precision: From segmentation to strategy

Precision oncology spans a spectrum of strategies. While some approaches, like personalized mRNA vaccines, rely on deep molecular profiling and individualized design, others, such as daraxonrasib, demonstrate broader activity across biomarker-defined populations.

As ASCO 2026 showed us, this range reinforces the need to integrate biology, diagnostics, and strategy at the outset. Even where patient selection is less restrictive, tools such as ctDNA and MRD can play important roles for monitoring response and guiding treatment decisions.

For EBPs, success in early-phase oncology increasingly depends on designing programs holistically by carefully considering mechanism of action, biomarker strategy, patient population, and clinical endpoints early to generate meaningful signals and support efficient development. 

A new foundation for oncology innovation